Immunologic Response to Inactivated Vaccine for Novel H1N1 Virus

Influenza Clinical Trial

Official title:

Assessment of the Effect of Age and Priming on the Immunological Response to an Inactivated Vaccine for Novel H1N1 Virus.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01023711
• Other study ID #: URMC 09-005
• Status: Completed
• Phase: N/A
• First received: December 1, 2009
• Last updated: April 24, 2015
• Start date: November 2009
• Est. completion date: July 2011

Study information

• Verified date: April 2015
• Source: University of Rochester
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to describe the immune response to a novel H1N1 influenza vaccination in healthy adults, and to understand the factors that allow healthy adults to respond to a single dose of vaccine even if they have never previously experience novel H1N1 disease or vaccination.

Description:

Studies have now determined that only a single dose of inactivated vaccine is needed for immunization against novel H1N1, but the reasons why adults appear to be ready to respond to a single dose are not known.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 107
• Est. completion date: July 2011
• Est. primary completion date: November 2010
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Aged 18-32 years, or 60 years and older

• No history of Novel H1N1 virus or vaccine

• Female not able to bear children or not pregnant and agrees to practice effective birth control

• Female negative pregnancy test

• Good Health

• Ability to understand and comply with protocol

• Provided Informed Consent

Exclusion Criteria:

• Previous history of vaccination against novel H1N1 or laboratory documented H1N1 infection

• Previous history of vaccination with A/New Jersey/76 vaccine (for subjects 60 & older

• History of egg allergy or is allergic to other components of the vaccine

• Women who are pregnant or breastfeeding or intends to get pregnant during the study period between enrollment & 30 days following vaccination

• Subject is immunosuppressed as the result of underlying illness or treatment with immunosuppressive or cytotoxic drugs or use of chemotherapy/radiation therapy in the preceding 36 months

• Subject has active neoplastic disease (excluding non-melanoma skin cancer or prostate cancer that is stable in the absence of therapy) or a history of any hematological malignancy. "Active" is defined as treatment within the past 5 years.

• Long term (greater than 2 weeks) use of oral or parental steroids, or high- dose inhaled steroids (>800 mcg/day of beclomethasone dipropionate or equivalent) within the preceding 6 months (nasal & topical steroids allowed)

• Received immunoglobulin or other blood product within 3 months prior to enrollment in this study

• Subject has received an inactivated vaccine within 2 weeks or a live vaccine within 4 weeks prior to enrollment or plans to receive another vaccine within the next 28 days

• Subject has an acute or chronic medical condition that, in the opinion of the investigator, would render vaccination unsafe or would interfere with the evaluation of responses. Those conditions include chronic conditions recognized as risk factors for influenza complications or as contraindicated for live vaccination, including chronic cardiac (exclusive of hypertension) or pulmonary conditions (including asthma), diabetes mellitus, or renal impairment

• Subject has an acute illness or an oral temperature greater then 99.9 F(37.7 C)within 3 days of enrollment or vaccination. Subject who has acute illness that was treated, symptoms resolved are eligible to enroll as long as treatment is complete & symptoms resolved > 3 days prior to enrollment.

• Subject is currently participating or plans to participate in a study that involves an experimental agent (vaccine, drug, biologic, device, blood product, or medication) or has received an experimental agent within 1 month of enrollment in this study, or intends to donate blood during this period.

• Subject has any condition that would, in the opinion of the investigator, place the subject at an unacceptable risk of injury or render the subject unable to meet the requirements of the protocol

• Subject has a diagnosis of schizophrenia, bi-polar disease, or other severe (disabling) chronic psychiatric diagnosis, or are receiving psychiatric drugs. Subjects who are receiving a single anti-depressant drug & are stable for at least 3 months prior to enrollment without decompensation are allowed enrollment into the study.

• Subject has a history of alcohol or drug abuse in the 5 years of enrollment.

• Subject has known human immunodeficiency virus, hepatitis B, or hepatitis C infection.

• Subject has a previous history of Guillain-Barre syndrome within 6 weeks of receipt of influenza vaccine

• Subject has any condition that the principal investigator (PI) believes may interfere with the successful completion of the study

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

• Influenza

Intervention

Biological:
• Inactivated H1N1 vaccine
0.5 ml IM into Deltoid region of arm
• Inactivated H1N1 vaccine
0.5 mL IM X 1 dose

Locations

Country	Name	City	State
United States	Vaccine Research Unit Room 3-5000	Rochester	New York

Sponsors (1)

Lead Sponsor	Collaborator
University of Rochester

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Determination of Immune Response to Vaccination.	Number of participants with a 4-fold or greater increase in serum HAI antibody from pre- to 28 day post-vaccination	28 days	No
Secondary	Assessment of the Reactogenicity Events Post Vaccination.	Number of subjects with reactogenicity events of grade 2 or higher within 7 days of vaccination	7 days	Yes